Stock exchange news | Navamedic

Read the latest news directly from the market.

Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland

Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient Read more

Navamedic ASA: Q2 and first half 2021 financial results

“We continue to deliver rapid growth for our specialty pharma product Mysimba and consumer health products Alflorex and ThermaCare. In Read more

Navamedic ASA: Invitation to 2021 Second quarter presentation

Navamedic ASA invites you to a presentation of the 2021 second quarter results on Friday, August 13th at 08.30 CET. The Read more

Treating the side-effects of the pandemic

Musculoskeletal pain is often a result of muscle tension and overexertion, psychological stress or working postures, often in combination with Read more

Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has won the tender for certain antibiotics to the Norwegian hospital market

As announced on 4 August 2020, Navamedic completed the acquisition of the marketing authorisations in the Nordics for a portfolio Read more

Obesity patient support program launched in Norway

Navamedic, a Nordic pharma company, specialized in the field of obesity and Observia, French e-health company specialized in patient engagement Read more

Navamedic ASA: Notice of Annual General Meeting

The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on Thursday, June 3rd 2021 at 13:00 (CET) Read more

Navamedic ASA: Q1 2021 financial

“In the first quarter of 2021, we continued to deliver growth in our underlying portfolio. The rapid growth of specialty Read more

Subscribe to stock exhange news